The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Isatuximab combination therapy for relapsed and refractory multiple myeloma | Results from the phase III IKEMA trial
May 12, 2020 saw the early release of results from the phase III IKEMA (NCT03275285) trial following recommendation from an Independent Data Monitoring Committee.1 The randomized, open label, multicenter study evaluated the clinical benefit of the anti-CD38 agent, isatuximab, in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone alone in patients with relapsed and/or refractory (RR) multiple myeloma (MM; RRMM) following 1 ‒ 3 prior lines of therapy.2
In this first planned interim analysis of the IKEMA trial, the addition of isatuximab to the carfilzomib plus dexamethasone regimen was associated with significantly improved progression-free survival (PFS) rates in patients with RRMM when compared to carfilzomib and dexamethasone alone. These data fulfil the primary endpoint for this study and no new safety concerns were observed.
IKEMA trial
- Isatuximab (10 mg/kg) was administered by intravenous (IV) infusion once weekly for 4 weeks, and then biweekly in 28-day cycles in combination with
- carfilzomib (IV, 20/56 mg/m2) twice weekly the first three weeks of each cycle
- dexamethasone (IV or oral, standard dose) for the entirety of treatment
- Primary endpoint: PFS
- Secondary endpoints: overall response rate, very good partial response or greater, minimal residual disease, complete response rate, overall survival, and safety.
- Key exclusion criteria:
- previously treated with carfilzomib
- primary refractory
- free light chain measurable disease only
- Eastern Cooperative Oncology Group (ECOG) performance status > 2
Isatuximab recently received approval in Europe and the US for the treatment of RRMM in combination with pomalidomide and dexamethasone.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content